Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study | Zendy

Daniel M. Musher | Zendy; Nancy Logan | Zendy; Adam Bressler | Zendy; David Johnson | Zendy; JeanFrançois Rossignol | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study

Author(s) -

Daniel M. Musher,

Nancy Logan,

Adam Bressler,

David Johnson,

JeanFrançois Rossignol

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/596552

Subject(s) - nitazoxanide , medicine , vancomycin , metronidazole , clostridium difficile , randomized controlled trial , confidence interval , surgery , antibiotics , gastroenterology , staphylococcus aureus , microbiology and biotechnology , biology , bacteria , genetics

Vancomycin is the only US Food and Drug Administration-approved drug for treatment of Clostridium difficile infection (CDI). Metronidazole has been widely used for this purpose but may be inferior to vancomycin, especially for hospitalized patients with severe disease. We report a prospective, double-blind, randomized controlled trial comparing nitazoxanide with vancomycin for treatment of CDI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research